Finland
Marginum, founded in 2020 and headquartered in Finland, is a promising early-stage medical technology startup. Its focus is on developing fluorescence-based tissue detection systems aimed at enhancing surgical outcomes, particularly in cancer surgeries, without disrupting current surgical workflows.
With its slogan, "A university-based medical technology startup developing fluorescence-based tissue detection systems," the company capitalizes on state-of-the-art research for improved surgical precision and cost-effectiveness. This enables it to deliver data-driven solutions that efficiently monitor tumor tissues during operations.
The company recently secured a €2.50M seed investment on 01 August 2025 from an impressive lineup of investors, including Redstone Capital, Lynx Financial 德石资本, Business Finland, Almaral, and Nostetta Ventures. This financial backing reflects confidence in Marginum's cross-disciplinary team, which collaborates with academic, clinical, and industry experts to ensure their technological solutions have strong clinical applicability.
